• Akebia Therapeutics disclosed publication of a post-hoc analysis from its global Phase 3 INNO2VATE program in Journal of American Society of Nephrology, meaning results have already been presented in peer-reviewed form.
• Analysis found vadadustat (Vafseo) outperformed darbepoetin alfa on a combined measure of death or hospitalization in adults with anemia due to chronic kidney disease receiving maintenance dialysis, supporting differentiation versus a standard ESA option.
• Update could strengthen commercial positioning for Vafseo in US dialysis anemia market, where product has been available since January 2025 for adults on dialysis for at least three months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605040800PRIMZONEFULLFEED9712099) on May 04, 2026, and is solely responsible for the information contained therein.